Giehler et al., 2022 - Google Patents
Epstein-Barr virus-driven B cell lymphoma mediated by a unique LMP1-TRAF6 complexGiehler et al., 2022
View PDF- Document ID
- 15767322946116024719
- Author
- Giehler F
- Ostertag M
- Sommermann T
- Weidl D
- Sterz K
- Kutz H
- Feller S
- Geerlof A
- Biesinger B
- Popowicz G
- Kirchmair J
- Kieser A
- Publication year
- Publication venue
- Research Square
External Links
Snippet
The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) drives viral B cell transformation andoncogenesis. LMP1's transforming activity depends on its cytoplasmic C- terminal activation region 2 (CTAR2), which induces NF-? B and JNK by engaging TNF …
- 241000701044 Human gammaherpesvirus 4 0 title abstract description 19
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reynolds et al. | Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene | |
| Dejardin | The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development | |
| Hostager et al. | Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation | |
| Wan et al. | Elucidation of the c-Jun N-terminal kinase pathway mediated by Epstein-Barr virus-encoded latent membrane protein 1 | |
| US20060223055A1 (en) | Methods and compositions for treatment of viral lnfection | |
| Giehler et al. | Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex | |
| Qiu et al. | A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis | |
| Floettmann et al. | Epstein–Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions | |
| KR100565819B1 (en) | Compounds that inhibit interaction between signal-transducing proteins and the glgfpdz/dhr domain and uses thereof | |
| Dawson et al. | The Epstein–Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1 | |
| AU2002256518B2 (en) | Inhibitors of receptor activator of NF-kappaB and uses thereof | |
| AU2002256518A1 (en) | Inhibitors of receptor activator of NF-kappaB and uses thereof | |
| Giehler et al. | Epstein-Barr virus-driven B cell lymphoma mediated by a unique LMP1-TRAF6 complex | |
| Hansen et al. | C-terminal sequences in R-Ras are involved in integrin regulation and in plasma membrane microdomain distribution | |
| US20040167072A1 (en) | Inhibitors of receptor activator of NF-kappaB and uses thereof | |
| Jeong et al. | STP-A11, an oncoprotein of Herpesvirus saimiri augments both NF-κB and AP-1 transcription activity through TRAF6 | |
| US20220380801A1 (en) | Tripartite systems for protein dimerization and methods of use | |
| US20090220490A1 (en) | Compositions and Assays for Inhibiting HCV Infection | |
| Boosani et al. | Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities | |
| Đukić | Interactions of HPV E6 Oncoproteins with Binding Partners: Implications on E6 Stability and Cellular Functions | |
| Khasnis | Investigating the regulation of B cell growth and survival genes by Epstein-Barr virus | |
| Lee et al. | Modulation of T-cell receptor signal transduction by herpesvirus signaling adaptor protein | |
| Benedyk | Structural and functional characterisation of pUL21, an α-herpesvirus phosphatase adaptor protein | |
| Tadimari Prabhakar | CK2 phosphorylation of human papillomavirus 16 E2 on serine 23 promotes interaction with TopBP1 and is critical for E2 plasmid retention function | |
| Bellaart et al. | TRIM37 employs peptide motif recognition and substrate-dependent oligomerization to prevent ectopic spindle pole assembly |